Large B-Cell Lymphoma After CD19 CAR-T Failure: Updated Real-World Outcomes, Prognostic Factors, and Prediction Models
{{output}}
Background Outcomes after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy failure in relapsed or refractory large B-cell lymphoma (LBCL) remain poor, and prognostic tools to guide subsequent management are limited. We evaluated real-world outcom... ...
